Abstract:
An important aspect of the management of patients with endometrial cancer (ER) is the
timely identification of risk groups, early signs of the onset and recurrence of the disease. There
is an active search for new markers for early diagnosis, detection of relapses and postoperative
monitoring of RE. Tumor necrosis factor alpha (TNFα) is a cytokine involved in the
pathogenesis of various forms of cancer, as well as associated with chronic inflammation,
obesity. The goal is to study the methylation of the TNFa gene in the OM and the possibility of
using it as a marker for forecasting, monitoring, and the risk of developing the OM. Materials
and methods. DNA methylation was determined by the method of pyrosequencing in
endometrial specimens taken from 10 patients with verified endometrial hyperplasia and 13
patients with RE when performing hysteroscopy with endometrial biopsy or endometrial
curettage. Results and discussion. The total degree of methylation of the TNFα gene DNA
promoter in the samples under study in patients with simple and / or complex nonatypical
endometrial hyperplasia was 62.6 ± 12.8% and was higher than in RE patients (34.7 ± 8.8%).
Findings. The results of the study showed the involvement of the epigenetic mechanism, which
is associated with hypomethylation of the TNFα gene promoter, which can lead to the activation
of the TNFα gene in RE. Determining the amount of methylation DNA promoter of the TNFα
gene can be used as a potential prognostic and diagnostic marker for ER.
